Moderna is reducing its global workforce by around 10% by the end of 2025 as demand for Covid-19 vaccines continues to weaken ...

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...

Five months after taking over the federal agency responsible for the health of all Americans, Robert F. Kennedy Jr. wants to overhaul an obscure but vital program that underpins the nation’s ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

17th Jul 2025 09:56 (Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles. The ...

Viral membrane proteins are the proteins of choice in vaccines but are difficult to produce quickly and reliably for use in vaccines, limiting rapid response during emerging outbreaks. Researchers ...

Nissan is closing its Oppama factory to reduce costs and will move production to Kyushu. The closure is part of a restructuring effort to boost profitability. The company has been financially strained ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

U.S. factories face job losses and uncertainty as tariffs rise, subsidies end, and manufacturers wait for clarity on trade policy and economic direction.